Sorafenib-Induced Hepatic Encephalopathy

Abstract

Get full access to this article

View all access options for this article.

References

Naranjo

, Busto

, Sellers

. A method for estimating the probability of adverse drug reaction. Clin Pharmacol Ther 1981-30:239–45.

Richly

, Schultheis

, Adamietz

. Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: results from a phase I extension trial. Eur J Cancer 2009;45:579–87.

Dharancy

, Romano

, Wolf

. Safety and preliminary results from a case-control study of sorafenib in patients with relapsed hepatocellular carcinoma after hepatic transplantation. Presented at: Journées Francophones d'Hepato-Gastroentérologie et d'Oncologie Digestive, March 19, 2009, Paris, France.

Drug information, research, clinical trial, news. Nexavar, Adverse Event Reports. wwwdruglib.com/druginfo/nexavar/.htm (accessed 2009 Sept 1).

Wörns

, Weinmann

, Pfingst

. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J Clin Gastroenterol 2009;43:489–95.